Zobrazeno 1 - 10
of 177
pro vyhledávání: '"Susan W. Barnett"'
Autor:
Zoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg, One B Dintwe, Faatima Laher Omar, Jia J Kee, Linda-Gail Bekker, Fatima Laher, Nivashnee Naicker, Ilesh Jani, Nyaradzo M Mgodi, Portia Hunidzarira, Modulakgota Sebe, Maurine D Miner, Laura Polakowski, Shelly Ramirez, Michelle Nebergall, Simbarashe Takuva, Lerato Sikhosana, Jack Heptinstall, Kelly E Seaton, Stephen De Rosa, Carlos A Diazgranados, Marguerite Koutsoukos, Olivier Van Der Meeren, Susan W Barnett, Niranjan Kanesa-Thasan, James G Kublin, Georgia D Tomaras, M Juliana McElrath, Lawrence Corey, Kathryn Mngadi, Paul Goepfert, HVTN 107 Protocol Team
Publikováno v:
PLoS Medicine, Vol 21, Iss 3, p e1004360 (2024)
BackgroundAdjuvants are widely used to enhance and/or direct vaccine-induced immune responses yet rarely evaluated head-to-head. Our trial directly compared immune responses elicited by MF59 versus alum adjuvants in the RV144-like HIV vaccine regimen
Externí odkaz:
https://doaj.org/article/909a7c021d8247d2955cca75b0f8a084
Autor:
Beatriz Perdiguero, Benedikt Asbach, Carmen E. Gómez, Josef Köstler, Susan W. Barnett, Marguerite Koutsoukos, Deborah E. Weiss, Anthony D. Cristillo, Kathryn E. Foulds, Mario Roederer, David C. Montefiori, Nicole L. Yates, Guido Ferrari, Xiaoying Shen, Sheetal Sawant, Georgia D. Tomaras, Alicia Sato, William J. Fulp, Raphael Gottardo, Song Ding, Jonathan L. Heeney, Giuseppe Pantaleo, Mariano Esteban, Ralf Wagner
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
To control HIV infection there is a need for vaccines to induce broad, potent and long-term B and T cell immune responses. With the objective to accelerate and maintain the induction of substantial levels of HIV-1 Env-specific antibodies and, at the
Externí odkaz:
https://doaj.org/article/6036c61a4c684d169531306cb6b2b597
Autor:
Luca Schifanella, Susan W Barnett, Massimiliano Bissa, Veronica Galli, Melvin N Doster, Monica Vaccari, Georgia D Tomaras, Xiaoying Shen, Sanjay Phogat, Ranajit Pal, David C Montefiori, Celia C LaBranche, Mangala Rao, Hung V Trinh, Robyn Washington-Parks, Namal P M Liyanage, Giacomo Gorini, Dallas R Brown, Frank Liang, Karin Loré, David J Venzon, William Magnanelli, Michelle Metrinko, Josh Kramer, Matthew Breed, Galit Alter, Ruth M Ruprecht, Genoveffa Franchini
Publikováno v:
PLoS Pathogens, Vol 16, Iss 4, p e1008531 (2020)
[This corrects the article DOI: 10.1371/journal.ppat.1008121.].
Externí odkaz:
https://doaj.org/article/de89ef036b2d42059a0aaccaf8620aca
Autor:
Luca Schifanella, Susan W Barnett, Massimiliano Bissa, Veronica Galli, Melvin N Doster, Monica Vaccari, Georgia D Tomaras, Xiaoying Shen, Sanjay Phogat, Ranajit Pal, David C Montefiori, Celia C LaBranche, Mangala Rao, Hung V Trinh, Robyn Washington-Parks, Namal P M Liyanage, Giacomo Gorini, Dallas R Brown, Frank Liang, Karin Loré, David J Venzon, William Magnanelli, Michelle Metrinko, Josh Kramer, Matthew Breed, Galit Alter, Ruth M Ruprecht, Genoveffa Franchini
Publikováno v:
PLoS Pathogens, Vol 15, Iss 12, p e1008121 (2019)
The ALVAC-HIV clade B/AE and equivalent SIV-based/gp120 + Alum vaccines successfully decreased the risk of virus acquisition in humans and macaques. Here, we tested the efficacy of HIV clade B/C ALVAC/gp120 vaccine candidates + MF59 or different dose
Externí odkaz:
https://doaj.org/article/ddf108f6beda493a8ef6fa3116999955
Autor:
Joseph R. Francica, Daniel E. Zak, Caitlyn Linde, Emilio Siena, Carrie Johnson, Michal Juraska, Nicole L. Yates, Bronwyn Gunn, Ennio De Gregorio, Barbara J. Flynn, Nicholas M. Valiante, Padma Malyala, Susan W. Barnett, Pampi Sarkar, Manmohan Singh, Siddhartha Jain, Margaret Ackerman, Munir Alam, Guido Ferrari, Andres Salazar, Georgia D. Tomaras, Derek T. O'Hagan, Alan Aderem, Galit Alter, Robert A. Seder
Publikováno v:
Blood Advances, Vol 1, Iss 25, Pp 2329-2342 (2017)
Abstract: Adjuvants have a critical role for improving vaccine efficacy against many pathogens, including HIV. Here, using transcriptional RNA profiling and systems serology, we assessed how distinct innate pathways altered HIV-specific antibody resp
Externí odkaz:
https://doaj.org/article/412a4dcf39fe46fa94a258dc035552c8
Autor:
Yingxia Wen, Hung V Trinh, Christine E Linton, Chiara Tani, Nathalie Norais, DeeAnn Martinez-Guzman, Priyanka Ramesh, Yide Sun, Frank Situ, Selen Karaca-Griffin, Christopher Hamlin, Sayali Onkar, Sai Tian, Susan Hilt, Padma Malyala, Rushit Lodaya, Ning Li, Gillis Otten, Giuseppe Palladino, Kristian Friedrich, Yukti Aggarwal, Celia LaBranche, Ryan Duffy, Xiaoying Shen, Georgia D Tomaras, David C Montefiori, William Fulp, Raphael Gottardo, Brian Burke, Jeffrey B Ulmer, Susan Zolla-Pazner, Hua-Xin Liao, Barton F Haynes, Nelson L Michael, Jerome H Kim, Mangala Rao, Robert J O'Connell, Andrea Carfi, Susan W Barnett
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0194266 (2018)
The RV144 Phase III clinical trial with ALVAC-HIV prime and AIDSVAX B/E subtypes CRF01_AE (A244) and B (MN) gp120 boost vaccine regime in Thailand provided a foundation for the future development of improved vaccine strategies that may afford protect
Externí odkaz:
https://doaj.org/article/c524038f512c48a39e68e221debb900c
Autor:
Gavin Churchyard, Koleka Mlisana, Shelly Karuna, Anna-Lise Williamson, Carolyn Williamson, Lynn Morris, Georgia D Tomaras, Stephen C De Rosa, Peter B Gilbert, Niya Gu, Chenchen Yu, Nonhlanhla N Mkhize, Tandile Hermanus, Mary Allen, Michael Pensiero, Susan W Barnett, Glenda Gray, Linda-Gail Bekker, David C Montefiori, James Kublin, Lawrence Corey
Publikováno v:
PLoS ONE, Vol 11, Iss 9, p e0161753 (2016)
BACKGROUND:The safety and immunogenicity of SAAVI DNA-C2 (4 mg IM), SAAVI MVA-C (2.9 x 109 pfu IM) and Novartis V2-deleted subtype C gp140 (100 mcg) with MF59 adjuvant in various vaccination regimens was evaluated in HIV-uninfected adults in South Af
Externí odkaz:
https://doaj.org/article/6d43c6ed52f448908e78006f87e2d4c2
Autor:
Carlo Zambonelli, Antu K Dey, Susan Hilt, Samuel Stephenson, Eden P Go, Daniel F Clark, Mark Wininger, Celia Labranche, David Montefiori, Hua-Xin Liao, Ronald I Swanstrom, Heather Desaire, Barton F Haynes, Andrea Carfi, Susan W Barnett
Publikováno v:
PLoS ONE, Vol 11, Iss 7, p e0157391 (2016)
The viral envelope glycoprotein (Env) is the major target for antibody (Ab)-mediated vaccine development against the Human Immunodeficiency Virus type 1 (HIV-1). Although several recombinant Env antigens have been evaluated in clinical trials, only t
Externí odkaz:
https://doaj.org/article/3bd711cd04e04af68ea0083b32fc53a5
Autor:
Iskra Tuero, Venkatramanan Mohanram, Thomas Musich, Leia Miller, Diego A Vargas-Inchaustegui, Thorsten Demberg, David Venzon, Irene Kalisz, V S Kalyanaraman, Ranajit Pal, Maria Grazia Ferrari, Celia LaBranche, David C Montefiori, Mangala Rao, Monica Vaccari, Genoveffa Franchini, Susan W Barnett, Marjorie Robert-Guroff
Publikováno v:
PLoS Pathogens, Vol 11, Iss 8, p e1005101 (2015)
Many viral infections, including HIV, exhibit sex-based pathogenic differences. However, few studies have examined vaccine-related sex differences. We compared immunogenicity and protective efficacy of monomeric SIV gp120 with oligomeric SIV gp140 in
Externí odkaz:
https://doaj.org/article/03dd5126b48944a0890b2f5773c2155f
Autor:
Russell Vassell, Yong He, Prasad Vennakalanti, Antu K Dey, Min Zhuang, Wei Wang, Yide Sun, Zohar Biron-Sorek, Indresh K Srivastava, Celia C LaBranche, David C Montefiori, Susan W Barnett, Carol D Weiss
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0128562 (2015)
The membrane proximal external region (MPER) of the gp41 subunit of the HIV-1 envelope glycoprotein (Env) contains determinants for broadly neutralizing antibodies and has remained an important focus of vaccine design. However, creating an immunogen
Externí odkaz:
https://doaj.org/article/2dbc550b61bf4314aa375f1a7113ff50